Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
- Title
- Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
- Author
- 송무곤
- Keywords
- Derived neutrophil/lymphocyte ratio; Glasgow prognostic score; DLBCL
- Issue Date
- 2019-12
- Publisher
- Korean Society of Hematology
- Citation
- Blood Research, v. 54, no. 4, page. 244-252
- Abstract
- Background Systemic inflammatory response can be associated with the prognosis of diffuse large B cell lymphoma (DLBCL). We investigated the systemic factors significantly related to clinical outcome in relapsed/refractory DLBCL.. Methods In 242 patients with DLBCL, several factors, including inflammatory markers were analyzed. We assessed for the correlation between the survivals [progression-free surviv-al (PFS) and overall survival (OS)] and prognostic factors. Results In these patients, a high derived neutrophil/lymphocyte ratio (dNLR) (PFS, HR=2.452, P=0.002; OS, HR=2.542, P=0.005), high Glasgow Prognostic Score (GPS) (PFS, HR=2.435, P=0.002; OS, HR=2.621, P=0.002), and high NCCN-IPI (PFS, HR=2.836, P=0.003; OS, HR=2.928, P=0.003) were significantly associated with survival in multi-variate analysis. Moreover, we proposed a risk stratification model based on dNLR, GPS, and NCCN-IPI, thereby distributing patients into 4 risk groups. There were significant differences in survival among the 4 risk groups (PFS, P<0.001; OS, P<0.001). Conclusion In conclusion, dNLR, GPS, and NCCN-IPI appear to be excellent prognostic parameters for survival in relapsed/refractory DLBCL.
- URI
- https://www.bloodresearch.or.kr/journal/view.html?doi=10.5045/br.2019.54.4.244https://repository.hanyang.ac.kr/handle/20.500.11754/157201
- ISSN
- 2287-979X; 2288-0011
- DOI
- 10.5045/br.2019.54.4.244
- Appears in Collections:
- COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
- Files in This Item:
- Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma.pdfDownload
- Export
- RIS (EndNote)
- XLS (Excel)
- XML